Company intelligence / Profile preview

jCyte, Inc.

Newport Beach, California, United Statesjcyte.com ↗

Ownership: Private
Development stage: Phase 3

Overview

jCyte’s lead program, jCell, has shown positive results in earlier clinical trials for retinitis pigmentosa. The company recently announced a positive pre–Phase 3 FDA Type B meeting and plans to advance to Phase 3 trials. There are currently no FDA-approved therapies for RP; the treatment uses minimally invasive intravitreal injection of allogeneic retinal progenitor cells to preserve or restore vision in patients with degenerative retinal diseases. In May 2020, a major licensing deal was signed with Santen Pharmaceutical for ex-US rights.

Therapeutic areas: Ophthalmology
Modalities: Allogeneic cell therapy (progenitor cell-based technology)
Industry: Biotech

Drug pipeline

2 assets

famzeretcel

1 more asset in the full pipeline.

Partnerships

Santen Pharmaceutical Co., Ltd. – licensing/commercialization agreement for Europe and Asia worth up to $252 million plus royalties on net sales outside the US.

Beyond the preview

Go deeper on jCyte, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jCyte, Inc..